Rucaparib: A New Lease of Life for Ovarian Cancer Patients
Abstract: High grade epithelial ovarian cancer, along with fallopian tube and primary peritoneal cancers are generally responsive (partially or completely) to platinum based chemotherapy [1]. Significant scientific evidence has proven Rucaparib to be of substantial promise as monotherapy for maintenance of ovarian cancer patients regardless of genetic mutation [2].